Hijazi Mohamad Ali, Gessner André, El-Najjar Nahed
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Beirut Arab University, Beirut P.O. Box 11-5020, Lebanon.
Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
Cancers (Basel). 2023 Jun 15;15(12):3199. doi: 10.3390/cancers15123199.
Despite the advancement in drug discovery for cancer therapy, drug repurposing remains an exceptional opportunistic strategy. This approach offers many advantages (faster, safer, and cheaper drugs) typically needed to overcome increased challenges, i.e., side effects, resistance, and costs associated with cancer therapy. However, not all drug classes suit a patient's condition or long-time use. For that, repurposing chronically used medications is more appealing. This review highlights the importance of repurposing anti-diabetic and anti-hypertensive drugs in the global fight against human malignancies. Extensive searches of all available evidence (up to 30 March 2023) on the anti-cancer activities of anti-diabetic and anti-hypertensive agents are obtained from multiple resources (PubMed, Google Scholar, ClinicalTrials.gov, Drug Bank database, ReDo database, and the National Institutes of Health). Interestingly, more than 92 clinical trials are evaluating the anti-cancer activity of 14 anti-diabetic and anti-hypertensive drugs against more than 15 cancer types. Moreover, some of these agents have reached Phase IV evaluations, suggesting promising official release as anti-cancer medications. This comprehensive review provides current updates on different anti-diabetic and anti-hypertensive classes possessing anti-cancer activities with the available evidence about their mechanism(s) and stage of development and evaluation. Hence, it serves researchers and clinicians interested in anti-cancer drug discovery and cancer management.
尽管癌症治疗药物研发取得了进展，但药物再利用仍然是一种特殊的机会主义策略。这种方法具有许多优势（更快、更安全、更便宜的药物），这些优势通常是克服癌症治疗中不断增加的挑战（即副作用、耐药性和成本）所必需的。然而，并非所有药物类别都适合患者的病情或长期使用。因此，重新利用长期使用的药物更具吸引力。这篇综述强调了在全球抗击人类恶性肿瘤的斗争中重新利用抗糖尿病和抗高血压药物的重要性。我们从多个资源（PubMed、谷歌学术、ClinicalTrials.gov、药物银行数据库、ReDo数据库和美国国立卫生研究院）获取了关于抗糖尿病和抗高血压药物抗癌活性的所有现有证据（截至2023年3月30日）的广泛搜索结果。有趣的是，超过92项临床试验正在评估14种抗糖尿病和抗高血压药物对超过15种癌症类型的抗癌活性。此外，其中一些药物已经进入IV期评估，表明有望作为抗癌药物正式发布。这篇全面的综述提供了关于具有抗癌活性的不同抗糖尿病和抗高血压药物类别的最新信息，以及关于它们的作用机制、开发和评估阶段的现有证据。因此，它为对抗癌药物发现和癌症管理感兴趣的研究人员和临床医生提供了帮助。
